A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Brentuximab vedotin (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Hodgkin's disease
Focus Adverse reactions; Therapeutic Use

08 Oct 2024 Status changed from suspended to active, no longer recruiting.
12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
12 Dec 2023 Results the efficacy and safety data on the full adult cohort of patients treated in Phase 2, presented at the 65th American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com